Thyrocare posts Rs 216 Cr revenue in Q2 FY26; profit rises 81%

Diagnostics major Thyrocare Technologies posted a strong performance in the second quarter of FY26, reporting strong growth in both revenue and profit, supported by higher testing volumes across its diagnostic and imaging segments.

The company’s consolidated revenue from operations grew 22% year-on-year (YoY) to Rs 216.5 crore in Q2 FY26 from Rs 177.36 crore in Q2 FY25, as per its filings with the stock exchanges. 

Sequentially, the company’s revenue rose 12% from Rs 193 crore in Q1 FY26. The growth was primarily driven by the diagnostic testing services segment, which contributed over 93% of total revenue, while the imaging services segment (including PET-CT and radiopharmaceuticals) accounted for Rs 14.2 crore during the quarter.

Thyrocare’s profit after tax jumped 81% YoY to Rs 47.9 crore in Q2 FY26, compared to Rs 26.4 crore in the corresponding quarter last year, aided by margin expansion and operational leverage. For the first half of FY26, the company recorded a net profit that grew 71% to Rs 86.1 crore from Rs 50.4 crore in H1 FY25.

The company’s EBITDA margin improved to 33%, with total expenses growing at a slower pace (10% YoY) than revenue. During the quarter, the cost of materials consumed rose to Rs 59.8 crore, while employee benefits expenses stood at Rs 33.2 crore.

Thyrocare’s board has also approved a 2:1 bonus issue, allotting two fully paid-up shares for every existing share held by shareholders as of the record date. The board also declared an interim dividend of Rs 7 per share for FY26, with October 24 set as the record date.

At the end of H1FY26, Thyrocare had a total current asset of Rs 323 crore with cash and bank balances of Rs 70 crore. The company is currently traded at Rs 1270.5 (as on 12.35 PM) with the total market capitalization of Rs 6,754 crore ($767 million).